Pharmacokinetics of an elevated dosage of micafungin in premature neonates

Pediatric Infectious Disease Journal

Volumn 28, Issue 5, 2009, Pages 412-415

  Smith, P Brian ^a   Walsh, Thomas J ^b   Hope, William ^c   Arrieta, Antonio ^d   Takada, Akitsugu ^e   Kovanda, Laura L ^f   Kearns, Gregory L ^g   Kaufman, David ^h   Sawamoto, Taiji ^f   Buell, Donald N ^f   Benjamin, Daniel K ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^e ASTELLAS PHARMA INC   (Japan)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^g UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antifungal; Candida; Dosing; Micafungin; Premature infants

Indexed keywords

BILIRUBIN; FR 195743; MICAFUNGIN; POTASSIUM; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; CANDIDA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GESTATIONAL AGE; HUMAN; HYPOCHLOREMIA; HYPOKALEMIA; HYPONATREMIA; MALE; MONOCYTOSIS; MYCOSIS; NEWBORN; OPEN STUDY; PREMATURITY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

EID: 67649559611     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181910e2d     Document Type: Article

References (21)

1. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285-291.
2. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.
3. Rowen JL. Mucocutaneous candidiasis. Semin Perinatol. 2003;27:406-413.
4. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-1151.
5. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharma-cokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
6. Hiemenz JP, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 2005;49:1331-1336.
7. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110-1115.
8. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-171.
9. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116:791-797.
10. Starke JR, Mason EO Jr, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987;155:766 -774.
11. Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 2005;49:5092-5098.
12. Nahata MC, Tallian KB, Force RW. Pharmacokinetics of fluconazole in young infants. Eur J Drug Metab Pharmacokinet. 1999;24:155-157.
13. Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993;54:269-277.
14. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45:1145-1152.
15. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38:47-51.
16. Mycamine [package insert]. Deerfield, IL: Astellas Pharma; 2005.
17. Benjamin DK Jr, Poole C, Steinbach WJ, et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003;112:634-640.
18. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46:1857-1869.
19. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J. 1998;17: 146-148.
20. Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52:663-667.
21. Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol. 2003;20:153-163.